Funding for this research was provided by:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (401700/2020-8)
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/210.181/ 2020)
Received: 25 November 2020
Accepted: 20 January 2021
First Online: 24 February 2021
Ethics approval and consent to participate
: The ethics review board approved the protocol of the study (Comitato Etico Regione Liguria, protocol no. 163/2020).
: The need for written informed consent was waived for retrospectively collected data. According to local regulations, consent was delayed after discharge for prospectively collected data in unconscious patients.
: Not applicable.
: Not applicable.
: Dr. Bassetti reports personal fees and other from Angelini, personal fees and other from AstraZeneca, other from Bayer, personal fees and other from Cubist, personal fees and other from Pfizer, personal fees and other from Menarini, personal fees and other from MSD, other from Nabriva, other from Paratek, other from Roche, other from Shionogi, other from Tetraphase, other from The Medicine Company, personal fees and other from Astellas Pharma Inc., personal fees from Gilead Sciences, personal fees from Teva, personal fees from Novartis, grants from Ranbaxy, personal fees from Correvio, personal fees from Molteni, personal fees from Thermo Fisher, outside the submitted work. Dr. Herrmann is cofounder and shareholder in OscillaVent, Inc, and consultant for ZOLL Medical Corporation, both outside the submitted work. Dr. Giacobbe reports personal fees from Stepstone Pharma GmbH, personal fees from MSD Italia, personal fees from Correvio Italia, outside the submitted work. Dr. Rocco reports personal fees from SANOFI as a DSMB member. All other authors declared no conflict of interest.